CytomX Therapeutics, Inc. Overview
Pro stress-test →CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering masked, conditionally activated biologics designed to localize to the tumor microenvironment. Through its proprietary PROBODY® platform, the company aims to unlock more potent, less toxic cancer therapies across multiple treatment modalities including antibody-drug conjugates, T-cell engagers, and immune modulators.
Strategic Profile
Pro stress-test →CytomX differentiates through its conditional activation platform technology that enhances tumor-targeting while reducing activity in healthy tissues, creating a broader therapeutic window. Strategic partnerships with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna strengthen non-dilutive revenue prospects and validate its technological approach, positioning it as an attractive acquisition target.
Competitive Landscape
Pro stress-test →CytomX competes in the oncology biologics space against established players and emerging biotech firms developing ADCs and T-cell engagers. Competitors include Seagen, Cellectar, and larger pharma companies' ADC programs. CytomX's differentiation lies in its conditional activation platform that reduces systemic toxicity while maintaining efficacy—a critical advantage in crowded immuno-oncology markets.
Industry Context
CytomX Therapeutics, Inc. operates in Biopharmaceutical - Oncology (Clinical-Stage Development).
Key facts
Founded: 2008 · Headquarters: South San Francisco, California · Employees: 102 · Revenue: $141.1M (TTM) · Market cap: $581M